Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion

被引:23
作者
Yilancioglu, Kaan [1 ]
Cokol, Murat [1 ,2 ,3 ]
机构
[1] Uskudar Univ, Fac Engn & Nat Sci, Istanbul, Turkey
[2] Harvard Med Sch, Lab Syst Pharmacol, Boston, MA 02115 USA
[3] Axcella Hlth, Cambridge, MA USA
关键词
PREDICTION; DRUGS;
D O I
10.1038/s41598-019-48410-y
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Combinations of more than two drugs are routinely used for the treatment of pathogens and tumors. High-order combinations may be chosen due to their non-overlapping resistance mechanisms or for favorable drug interactions. Synergistic/antagonistic interactions occur when the combination has a higher/lower effect than the sum of individual drug effects. The standard treatment of Mycobacterium tuberculosis (Mtb) is an additive cocktail of three drugs which have different targets. Herein, we experimentally measured all 190 pairwise interactions among 20 antibiotics against Mtb growth. We used the pairwise interaction data to rank all possible high-order combinations by strength of synergy/antagonism. We used drug interaction profile correlation as a proxy for drug similarity to establish exclusion criteria for ideal combination therapies. Using this ranking and exclusion design (R/ED) framework, we modeled ways to improve the standard 3-drug combination with the addition of new drugs. We applied this framework to find the best 4-drug combinations against drug-resistant Mtb by adding new exclusion criteria to R/ED. Finally, we modeled alternating 2-order combinations as a cycling treatment and found optimized regimens significantly reduced the overall effective dose. R/ED provides an adaptable framework for the design of high-order drug combinations against any pathogen or tumor.
引用
收藏
页数:11
相关论文
共 34 条
[1]  
BERENBAUM MC, 1989, PHARMACOL REV, V41, P93
[2]   Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives [J].
Bulusu, Krishna C. ;
Guha, Rajarshi ;
Mason, Daniel J. ;
Lewis, Richard P. I. ;
Muratov, Eugene ;
Motamedi, Yasaman Kalantar ;
Cokol, Murat ;
Bender, Andreas .
DRUG DISCOVERY TODAY, 2016, 21 (02) :225-238
[3]   Chemogenomics and orthology-based design of antibiotic combination therapies [J].
Chandrasekaran, Sriram ;
Cokol-Cakmak, Melike ;
Sahin, Nil ;
Yilancioglu, Kaan ;
Kazan, Hilal ;
Collins, James J. ;
Cokol, Murat .
MOLECULAR SYSTEMS BIOLOGY, 2016, 12 (05)
[4]   Network-based prediction of drug combinations [J].
Cheng, Feixiong ;
Kovacs, Istvan A. ;
Barabasi, Albert-Laszlo .
NATURE COMMUNICATIONS, 2019, 10 (1)
[5]   Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis [J].
Cokol, Murat ;
Kuru, Nurdan ;
Bicak, Ece ;
Larkins-Ford, Jonah ;
Aldridge, Bree B. .
SCIENCE ADVANCES, 2017, 3 (10)
[6]  
Cokol Murat, 2013, Curr Drug Discov Technol, V10, P106
[7]   Systematic exploration of synergistic drug pairs [J].
Cokol, Murat ;
Chua, Hon Nian ;
Tasan, Murat ;
Mutlu, Beste ;
Weinstein, Zohar B. ;
Suzuki, Yo ;
Nergiz, Mehmet E. ;
Costanzo, Michael ;
Baryshnikova, Anastasia ;
Giaever, Guri ;
Nislow, Corey ;
Myers, Chad L. ;
Andrews, Brenda J. ;
Boone, Charles ;
Roth, Frederick P. .
MOLECULAR SYSTEMS BIOLOGY, 2011, 7
[8]   Diagonal Method to Measure Synergy Among Any Number of Drugs [J].
Cokol-Cakmak, Melike ;
Bakan, Feray ;
Cetiner, Selim ;
Cokol, Murat .
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2018, (136)
[9]   Analysis of drug combinations: current methodological landscape [J].
Foucquier, Julie ;
Guedj, Mickael .
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2015, 3 (03)
[10]  
Fox W, 1999, INT J TUBERC LUNG D, V3, pS231